The securities of Imagion Biosystems Limited (‘IBX’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release of an announcement regarding a capital raising.
Read the Suspension from Official Quotation announcement.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
July 15, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging